BioCentury
ARTICLE | Clinical News

Patanase olopatadine hydrochloride regulatory update

August 3, 2009 7:00 AM UTC

Alcon disclosed that last quarter it submitted an sNDA to FDA for Patanase olopatadine hydrochloride nasal spray to treat seasonal allergic rhinitis in pediatric patients ages 6 months to 12 years. Th...